Synaptogenix (SNPX) Competitors $3.07 +0.50 (+19.46%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends SNPX vs. NRXP, CARA, ACXP, MRNS, TXMD, HCWB, AIM, SLGL, PMCB, and AWHShould you be buying Synaptogenix stock or one of its competitors? The main competitors of Synaptogenix include NRx Pharmaceuticals (NRXP), Cara Therapeutics (CARA), Acurx Pharmaceuticals (ACXP), Marinus Pharmaceuticals (MRNS), TherapeuticsMD (TXMD), HCW Biologics (HCWB), AIM ImmunoTech (AIM), Sol-Gel Technologies (SLGL), PharmaCyte Biotech (PMCB), and Aspira Women's Health (AWH). These companies are all part of the "pharmaceutical products" industry. Synaptogenix vs. NRx Pharmaceuticals Cara Therapeutics Acurx Pharmaceuticals Marinus Pharmaceuticals TherapeuticsMD HCW Biologics AIM ImmunoTech Sol-Gel Technologies PharmaCyte Biotech Aspira Women's Health Synaptogenix (NASDAQ:SNPX) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations. Is SNPX or NRXP more profitable? NRx Pharmaceuticals' return on equity of 0.00% beat Synaptogenix's return on equity.Company Net Margins Return on Equity Return on Assets SynaptogenixN/A -42.14% -29.42% NRx Pharmaceuticals N/A N/A -449.16% Do analysts rate SNPX or NRXP? Synaptogenix currently has a consensus target price of $14.00, suggesting a potential upside of 356.03%. NRx Pharmaceuticals has a consensus target price of $32.00, suggesting a potential upside of 2,033.33%. Given NRx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe NRx Pharmaceuticals is more favorable than Synaptogenix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synaptogenix 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00NRx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Do institutionals and insiders believe in SNPX or NRXP? 10.3% of Synaptogenix shares are held by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are held by institutional investors. 2.7% of Synaptogenix shares are held by insiders. Comparatively, 19.0% of NRx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has higher valuation and earnings, SNPX or NRXP? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSynaptogenixN/AN/A-$6.04MN/AN/ANRx PharmaceuticalsN/AN/A-$30.15M-$2.14-0.70 Does the MarketBeat Community believe in SNPX or NRXP? NRx Pharmaceuticals received 11 more outperform votes than Synaptogenix when rated by MarketBeat users. Likewise, 100.00% of users gave NRx Pharmaceuticals an outperform vote while only 66.67% of users gave Synaptogenix an outperform vote. CompanyUnderperformOutperformSynaptogenixOutperform Votes266.67% Underperform Votes133.33% NRx PharmaceuticalsOutperform Votes13100.00% Underperform VotesNo Votes Does the media refer more to SNPX or NRXP? In the previous week, NRx Pharmaceuticals had 1 more articles in the media than Synaptogenix. MarketBeat recorded 2 mentions for NRx Pharmaceuticals and 1 mentions for Synaptogenix. NRx Pharmaceuticals' average media sentiment score of 1.46 beat Synaptogenix's score of 0.00 indicating that NRx Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Synaptogenix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NRx Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, SNPX or NRXP? Synaptogenix has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500. Comparatively, NRx Pharmaceuticals has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500. SummaryNRx Pharmaceuticals beats Synaptogenix on 11 of the 14 factors compared between the two stocks. Ad Behind the Markets⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Click here for the ticker >>> Get Synaptogenix News Delivered to You Automatically Sign up to receive the latest news and ratings for SNPX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNPX vs. The Competition Export to ExcelMetricSynaptogenixPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.16M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E RatioN/A10.5589.7417.16Price / SalesN/A196.061,117.09117.04Price / CashN/A57.1643.1037.86Price / Book0.125.094.784.78Net Income-$6.04M$151.83M$120.31M$225.60M7 Day Performance14.13%-2.14%-1.92%-1.23%1 Month Performance18.08%-4.56%13.65%0.46%1 Year Performance-54.85%8.87%28.34%15.24% Synaptogenix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNPXSynaptogenix1.3944 of 5 stars$3.07+19.5%$14.00+356.0%-54.5%$4.16MN/A0.004News CoverageGap UpHigh Trading VolumeNRXPNRx Pharmaceuticals3.2971 of 5 stars$1.20flat$32.00+2,566.7%-96.5%$14.51MN/A-0.562News CoveragePositive NewsCARACara Therapeutics4.2221 of 5 stars$0.26-1.5%$2.32+799.2%-29.0%$14.15M$8.69M-0.1555News CoverageGap DownACXPAcurx Pharmaceuticals1.3843 of 5 stars$0.83-3.5%$12.00+1,354.5%-77.0%$13.94MN/A-0.783Gap UpMRNSMarinus Pharmaceuticals4.3127 of 5 stars$0.25-5.7%$4.79+1,832.1%-97.6%$13.67M$31.47M-0.10110Analyst ForecastNews CoverageTXMDTherapeuticsMD0.4365 of 5 stars$1.18-3.3%N/A-53.8%$13.61M$1.30M0.00420Analyst ForecastGap UpHigh Trading VolumeHCWBHCW Biologics0.4069 of 5 stars$0.36-0.3%N/A-60.4%$13.46M$3.50M-0.3640Gap DownAIMAIM ImmunoTech2.3707 of 5 stars$0.21-4.1%$2.75+1,209.5%-60.4%$13.39M$190,000.00-0.4720SLGLSol-Gel Technologies2.4264 of 5 stars$0.47-2.8%$5.00+973.2%-66.5%$12.98M$1.55M-1.3650PMCBPharmaCyte Biotech0.4225 of 5 stars$1.69-1.7%N/A-24.8%$12.98MN/A2.612Earnings ReportAWHAspira Women's Health1.3425 of 5 stars$0.75+0.6%$4.40+483.6%-69.7%$12.57M$9.15M-0.62110Analyst Forecast Related Companies and Tools Related Companies NRx Pharmaceuticals Alternatives Cara Therapeutics Alternatives Acurx Pharmaceuticals Alternatives Marinus Pharmaceuticals Alternatives TherapeuticsMD Alternatives HCW Biologics Alternatives AIM ImmunoTech Alternatives Sol-Gel Technologies Alternatives PharmaCyte Biotech Alternatives Aspira Women's Health Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SNPX) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredMUST SEE: The most important video in the world right now?If you have a significant amount of money in the stock market right now — or if you're sitting on the sideline...InvestorPlace | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synaptogenix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synaptogenix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SNPX Stock Alerts